Open AccessGenetic Markers for SSG Resistance in Leishmania donovani and SSG Treatment Failure in Visceral Leishmaniasis Patients of the Indian Subcontinent
Author(s) -
Manu Vanaerschot,
Saskia Decuypere,
Tim Downing,
Hideo Imamura,
Olivia Stark,
Simonne De Doncker,
Syamal Roy,
Bart Ostyn,
Louis Maes,
Basudha Khanal,
Marleen Boelaert,
Gabriele Schönian,
Matthew Berriman,
François Chappuis,
JeanClaude Dujardin,
Shyam Sundar,
Suman Rijal
Publication year - 2012
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jis424
Subject(s) - leishmania donovani , indian subcontinent , leishmaniasis , visceral leishmaniasis , leishmania , biology , immunology , amastigote , parasite hosting , world wide web , history , ancient history , computer science
The current standard to assess pentavalent antimonial (SSG) susceptibility of Leishmania is a laborious in vitro assay of which the result has little clinical value because SSG-resistant parasites are also found in SSG-cured patients. Candidate genetic markers for clinically relevant SSG-resistant parasites identified by full genome sequencing were here validated on a larger set of clinical strains. We show that 3 genomic locations suffice to specifically detect the SSG-resistant parasites found only in patients experiencing SSG treatment failure. This finding allows the development of rapid assays to monitor the emergence and spread of clinically relevant SSG-resistant Leishmania parasites.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom